| Q47624664 | A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma |
| Q41272473 | A diagnostically difficult case of a cellular pleural fluid: Morphology, immunohistochemistry, and fluorescence in situ hybridization study |
| Q92383067 | A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations |
| Q38888134 | Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients. |
| Q90612159 | Application of immunohistochemistry in diagnosis and management of malignant mesothelioma |
| Q85236158 | BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations |
| Q46024349 | BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions. |
| Q43191497 | CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival |
| Q64288080 | CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure |
| Q48215789 | CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry |
| Q38118298 | Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers |
| Q47836088 | Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma |
| Q91106403 | Cyclin D1 immunohistochemical staining to separate benign from malignant mesothelial proliferations |
| Q33470425 | Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma |
| Q46644119 | Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16. |
| Q28395184 | DNA copy number gains in malignant pleural mesothelioma |
| Q36467429 | Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue |
| Q54463086 | Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. |
| Q40165833 | Diffuse intrapulmonary malignant mesothelioma presenting with miliary pulmonary nodules: A case report |
| Q87355827 | Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach |
| Q90346713 | Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma |
| Q34337640 | FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma |
| Q28389535 | Factors that impact susceptibility to fiber-induced health effects |
| Q90390482 | Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q28394028 | Guidelines for the diagnosis and treatment of malignant pleural mesothelioma |
| Q92969758 | Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma |
| Q91623027 | Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas |
| Q58861769 | Interphase fluorescent in situ hybridization deletion analysis of the 9p21 region and prognosis in childhood acute lymphoblastic leukaemia (ALL): results from a prospective analysis of 519 Nordic patients treated according to the NOPHO-ALL 2000 proto |
| Q61811444 | Localized malignant pleural mesothelioma arising in the interlobar fissure: a unique surgical case masquerading clinicopathologically as primary lung adenocarcinoma |
| Q92377743 | Malignant mesothelioma in situ: morphologic features and clinical outcome |
| Q104515299 | Malignant pleural neoplasm with both differentiation of epithelioid mesothelioma and squamous-cell carcinoma, a rare phenomena |
| Q49546275 | Mesothelioma |
| Q82400088 | Metastatic peritoneal mesothelioma in the setting of recurrent ascites: a case report |
| Q96171992 | Molecular characterization of diffuse malignant peritoneal mesothelioma |
| Q38107102 | Molecular pathogenesis of malignant mesothelioma |
| Q34602201 | Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology |
| Q55078347 | Novel insights and recent discoveries on the genetics and pathogenesis of malignant mesothelioma. |
| Q51559692 | Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses. |
| Q52652980 | Post-irradiation pericardial malignant mesothelioma with deletion of p16: a case report. |
| Q33390251 | Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas |
| Q54112034 | RETRACTED: Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells. |
| Q98226319 | Reactive mesothelial hyperplasia mimicking mesothelioma in an African green monkey (Chlorocebus aethiops) |
| Q97551661 | Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology |
| Q48098208 | The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma. |
| Q54737674 | The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma. |
| Q38950690 | The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma |
| Q48231392 | Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections |
| Q38843154 | Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations |
| Q44404948 | Well-differentiated papillary mesothelioma, possibly giving rise to diffuse malignant mesothelioma: a case report |
| Q48883637 | Young investigator challenge: MicroRNA-21/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology. |